Stock CAMX CAMURUS AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Camurus AB

Equities

CAMX

SE0007692850

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:57 2024-04-26 am EDT 		5-day change 1st Jan Change
490 SEK +2.81% Intraday chart for Camurus AB +1.03% -8.92%
Apr. 17 Certain Shares of Camurus AB are subject to a Lock-Up Agreement Ending on 17-APR-2024. CI
Apr. 02 Camurus AB Announces Board Resignations CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 4,363 10,109 8,268 14,000 29,926 28,236 - -
Enterprise Value (EV) 1 4,032 9,673 7,882 13,461 28,760 26,407 25,419 23,613
P/E ratio -13.6 x -58.6 x -90.8 x 260 x 71.7 x 96.8 x 30.7 x 14.3 x
Yield - - - - - - - -
Capitalization / Revenue 41.3 x 30.1 x 13.8 x 14.6 x 17.4 x 15.1 x 9.68 x 6.45 x
EV / Revenue 38.2 x 28.8 x 13.1 x 14.1 x 16.8 x 14.1 x 8.72 x 5.4 x
EV / EBITDA -11.5 x -49.9 x -92.3 x 159 x 53.3 x 68.8 x 21.9 x 10.9 x
EV / FCF -9.35 x -39.9 x -53.1 x 136 x 48.2 x 109 x 25 x 11.1 x
FCF Yield -10.7% -2.5% -1.88% 0.74% 2.07% 0.92% 4% 8.98%
Price to Book 6.91 x 11.9 x 9.67 x 14 x 20.7 x 13.3 x 8.88 x 5.78 x
Nbr of stocks (in thousands) 51,637 54,234 54,829 55,423 55,624 57,624 - -
Reference price 2 84.50 186.4 150.8 252.6 538.0 490.0 490.0 490.0
Announcement Date 2/12/20 2/11/21 2/16/22 2/14/23 2/15/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 105.6 336 601 956.3 1,717 1,873 2,916 4,375
EBITDA 1 -351 -193.7 -85.37 84.89 539.9 384 1,162 2,166
EBIT 1 -360 -205.2 -111 71.96 525.9 367 1,144 2,142
Operating Margin -340.91% -61.08% -18.47% 7.52% 30.63% 19.59% 39.22% 48.95%
Earnings before Tax (EBT) 1 -361.6 -206.6 -111.8 73.12 549.3 387 1,164 2,155
Net income 1 -289.9 -167.3 -90.45 55.55 431.4 314.1 939.7 1,794
Net margin -274.53% -49.78% -15.05% 5.81% 25.13% 16.77% 32.23% 41.02%
EPS 2 -6.230 -3.180 -1.660 0.9700 7.500 5.061 15.96 34.38
Free Cash Flow 1 -431.4 -242.2 -148.4 99.29 596.8 243 1,017 2,120
FCF margin -408.56% -72.07% -24.69% 10.38% 34.76% 12.97% 34.87% 48.46%
FCF Conversion (EBITDA) - - - 116.97% 110.53% 63.29% 87.5% 97.88%
FCF Conversion (Net income) - - - 178.74% 138.32% 77.37% 108.21% 118.16%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/12/20 2/11/21 2/16/22 2/14/23 2/15/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 154 183 220.3 226.7 241.4 268 284 674.3 384 374.6 427.9 463.4 511.8 532.3
EBITDA 1 -6.305 -10.1 7.928 10.04 44.28 22.64 77.6 379.4 107.5 -24.65 67.2 76.44 125.7 104
EBIT 1 -6.305 -18 4.791 6.915 41.37 18.88 74.34 376.1 104 -28.54 63.71 72.95 122.2 100.5
Operating Margin -4.09% -9.84% 2.17% 3.05% 17.14% 7.04% 26.17% 55.77% 27.1% -7.62% 14.89% 15.74% 23.89% 18.88%
Earnings before Tax (EBT) 1 -6.629 -18.44 4.498 6.622 41.51 20.49 76.87 380.6 109.8 -18.01 67.11 76.38 125.7 104
Net income 1 -6.167 -14.02 -0.752 8.239 35 13.07 58.83 301.4 86.4 -15.21 53.58 60.96 99.96 82.94
Net margin -4% -7.66% -0.34% 3.63% 14.5% 4.88% 20.71% 44.7% 22.5% -4.06% 12.52% 13.15% 19.53% 15.58%
EPS 2 -0.1100 -0.2600 -0.0100 0.1400 0.6100 0.2300 1.020 5.240 1.500 -0.2700 0.4566 0.6375 1.848 1.695
Dividend per Share 2 - - - - - - - - - - - - - -
Announcement Date 11/4/21 2/16/22 5/12/22 7/15/22 11/10/22 2/14/23 5/10/23 7/18/23 11/9/23 2/15/24 - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 331 436 386 539 1,165 1,829 2,817 4,623
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -431 -242 -148 99.3 597 243 1,017 2,120
ROE (net income / shareholders' equity) -65.6% -22.6% -10.7% 6.03% 34.7% 14.9% 41.2% 55.3%
ROA (Net income/ Total Assets) - -18.4% -8.51% 4.65% 26.9% 10.2% 37.7% 42.4%
Assets 1 - 908.1 1,063 1,194 1,607 3,077 2,493 4,229
Book Value Per Share 2 12.20 15.60 15.60 18.10 26.00 36.80 55.20 84.80
Cash Flow per Share - - - - - - - -
Capex 1 4.63 3.33 4.94 1.91 10.1 29.5 17.8 36.2
Capex / Sales 4.39% 0.99% 0.82% 0.2% 0.59% 1.57% 0.61% 0.83%
Announcement Date 2/12/20 2/11/21 2/16/22 2/14/23 2/15/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Camurus AB

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
490 SEK
Average target price
577.2 SEK
Spread / Average Target
+17.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CAMURUS AB Stock Camurus AB
-8.92% 2.58B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CAMX Stock
  4. Financials Camurus AB